BRAF inhibitor

This page covers all BRAF inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting BRAF V600E.

Targets

BRAF V600E

Marketed (1)

• Vemurafenib (VEM) · Abramson Cancer Center at Penn Medicine · Oncology
  Vemurafenib is a small-molecule inhibitor that selectively blocks the BRAF V600E kinase mutation found in melanoma and other cancers.

Phase 3 pipeline (1)

• GSK2118436 · M.D. Anderson Cancer Center · Oncology
  GSK2118436 is a BRAF V600E inhibitor that blocks mutant BRAF kinase signaling in melanoma cells.